Pulse Biosciences (NASDAQ:PLSE) Trading Up 9.2% – What’s Next?

14 May 2026, 14:21 by Teresa Graham · The Cerbat Gem

Pulse Biosciences, Inc (NASDAQ:PLSE – Get Free Report)’s stock price shot up 9.2% on Thursday . The stock traded as high as $26.00 and last traded at $26.1580. 174,175 shares were traded during trading, a decline of 45% from the average session volume of 317,707 shares. The stock had previously closed at $23.96.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on PLSE. Oppenheimer restated an “outperform” rating and set a $30.00 target price on shares of Pulse Biosciences in a report on Friday, February 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Tuesday, April 21st. Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. Finally, Mizuho set a $30.00 target price on shares of Pulse Biosciences in a research note on Friday, February 6th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $30.00.

Get Our Latest Research Report on Pulse Biosciences

Pulse Biosciences Stock Performance

The business’s 50 day simple moving average is $21.03 and its 200-day simple moving average is $17.69. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of -24.41 and a beta of 1.63.

Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. As a group, sell-side analysts expect that Pulse Biosciences, Inc will post -1.29 EPS for the current year.

Insider Activity at Pulse Biosciences

In other Pulse Biosciences news, Director Robert W. Duggan bought 660,233 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $19.69 per share, with a total value of $12,999,987.77. Following the completion of the purchase, the director directly owned 48,211,433 shares in the company, valued at approximately $949,283,115.77. This trade represents a 1.39% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, insider Kevin Patrick Danahy sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $23.64, for a total transaction of $118,200.00. Following the sale, the insider directly owned 43,298 shares of the company’s stock, valued at approximately $1,023,564.72. This represents a 10.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 45,000 shares of company stock valued at $1,061,400 over the last ninety days. Insiders own 74.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its position in Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after acquiring an additional 680 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after buying an additional 2,156 shares during the period. Russell Investments Group Ltd. grew its position in shares of Pulse Biosciences by 44.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock worth $79,000 after buying an additional 1,372 shares during the period. KLP Kapitalforvaltning AS grew its position in shares of Pulse Biosciences by 136.0% during the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock worth $104,000 after buying an additional 3,400 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Pulse Biosciences during the 2nd quarter worth approximately $158,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

(Get Free Report)

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.